Sutro Biopharma approved a 1-for-10 reverse stock split of its common stock.
The reverse stock split aims to meet Nasdaq's minimum bid price requirement.
The stock split will be effective on December 3, 2025.
Reverse Stock Split Ratio
Approved at a ratio of 1-for-10 to reduce outstanding common stock shares.
Trading Symbol
Stock will continue trading under the existing symbol 'STRO' with a new CUSIP number.
Stockholders' Approval
The reverse stock split was approved at the 2025 annual meeting of stockholders.
- The reverse stock split will reduce the number of outstanding common stock shares significantly.
- Proportionate adjustments will be made to equity awards and employee stock purchase plan shares.
- No change to authorized shares or par value per share as a result of the reverse split.
Sutro Biopharma's reverse stock split is a strategic move to regain Nasdaq compliance and streamline its share structure.